NCT04058392View on ClinicalTrials.gov

Camu Camu in ART-treated People Living with HIV

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

July 20, 2022

Study Completion Date

July 20, 2022

Conditions
HIV Infections
Interventions
BIOLOGICAL

Camu Camu Capsules

Camu Camu powder encapsulated (500mg each). 2 capsules per day will be used for this study

Trial Locations (1)

H4A 3J1

Mcgill University Health Center, Montreal

All Listed Sponsors
lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT04058392 - Camu Camu in ART-treated People Living with HIV | Biotech Hunter | Biotech Hunter